After Anti-TNF Fails in Children With IBD: What a 2026 Meta-Analysis Found About Ustekinumab

Inflammatory bowel disease (IBD) in children, while less common than in adults, tends to follow a more aggressive course. A meaningful proportion of children with Crohn's disease or ulcerative colitis do not respond to first-line therapies, or lose response to them over time. Anti-TNF biologics, drugs that block tumour necrosis factor-alpha to reduce gut inflammation, are typically among the first biologics tried when standard treatment is insufficient. When they fail, families and clinical teams face a genuinely difficult question: what comes next?

Ustekinumab (brand name Stelara) is a biologic that works through a different mechanism. Rather than blocking TNF-alpha, it targets interleukin-12 and interleukin-23, proteins involved in driving chronic inflammatory responses. The NHS lists ustekinumab as one of the biological medicines used to treat Crohn's disease, including in paediatric patients (NHS, Crohn's disease treatment). However, the evidence base in children specifically, and particularly in children who have already failed anti-TNF therapy, has until recently remained limited.

What the 2026 Meta-Analysis Set Out to Do

A meta-analysis published on 20 July 2026 in BMC Gastroenterology attempted to pool the available paediatric data to give a clearer picture (Heng Z et al., BMC Gastroenterology, 2026). The researchers searched PubMed, the Cochrane Library, Embase, and Web of Science from inception through August 2025, identifying studies that reported outcomes of ustekinumab in paediatric IBD patients who had previously not responded to or lost response to anti-TNF therapy.

After screening, 15 studies covering 653 paediatric patients were included in the analysis. Pooled estimates were calculated using fixed- or random-effects models depending on statistical heterogeneity across studies.

What the Data Showed

Clinical remission. The pooled clinical remission rate was 57% (95% CI: 28%-86%) at 8-16 weeks of treatment. By 52 weeks, that figure rose to 68% (95% CI: 58%-79%). When broken down by diagnosis, remission at week 52 was 69% in children with Crohn's disease and 65% in those with ulcerative colitis.

Steroid-free remission. Among the outcomes most relevant to longer-term wellbeing, steroid-free clinical remission was 44% (95% CI: 38%-49%) at 8-16 weeks and 58% (95% CI: 45%-70%) at week 52. Reducing or eliminating corticosteroid dependence is a meaningful treatment goal in paediatric IBD, given the growth and developmental effects of long-term steroid use.

Mucosal and biochemical remission. The pooled endoscopic remission rate was 42% (95% CI: 35%-49%), and the biochemical remission rate, typically measured using inflammatory markers such as C-reactive protein or faecal calprotectin, was 63% (95% CI: 40%-87%).

Safety. Adverse events of any kind were reported in 20% of participants (95% CI: 9%-30%). Serious adverse events, however, occurred in only 1% of participants (95% CI: 0%-2%). The authors did not report treatment-related malignancies or deaths.

Important Limitations to Keep in Mind

The meta-analysis carries several caveats that the authors themselves highlighted. The confidence intervals for some outcomes are wide, reflecting substantial heterogeneity across the 15 included studies. This means the true average effect in a given clinical setting could be meaningfully higher or lower than the pooled estimate. The UC subgroup in particular, while showing a clinical remission rate of 65% at week 52, was noted by the authors to provide only preliminary evidence warranting cautious interpretation, given the limited number of studies focused specifically on children with UC.

The included studies varied in their follow-up duration, outcome definitions, and patient populations. These differences, while expected in any meta-analysis of a relatively new evidence area, mean that the pooled numbers are useful as broad signals rather than precise predictions for any individual patient.

What This Means for Families

This meta-analysis is one of the largest and most recent syntheses of ustekinumab evidence in paediatric anti-TNF-refractory IBD. It suggests that ustekinumab is associated with clinically meaningful remission rates in this difficult-to-treat population and that serious side effects appear uncommon. For Crohn's disease in particular, the consistency of results across multiple studies provides a reasonably robust signal.

For ulcerative colitis, the picture is more preliminary. The available data are encouraging but thinner, and families of children with UC should be aware that the evidence base is still developing.

No meta-analysis can substitute for the judgement of the specialist team who knows your child's history, prior medications, and current disease activity. If your child has not responded to anti-TNF treatment, this research is one piece of information that may be relevant to discuss with their paediatric gastroenterologist.

Always consult your doctor or specialist before making any changes to your child's treatment.